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1. Preamble beginning of the PM era. In some situations, efﬁcacy of pacingGuidelines summarize and evaluate all available evidences,
at the time of the writing process, on a particular issue, with
the aim of assisting physicians in selecting the best manage-
ment strategies for an individual patient with a given condi-
tion, taking into account the impact on outcome, as well as
the risk–beneﬁt ratio of particular diagnostic or therapeutic
means. The level of evidence and the strength of recommen-
dation of particular treatment options were weighed and
graded according to predeﬁned scales, as outlined in Tables 1
and 2. However, the ﬁnal decisions concerning an individual
patient must be made by the responsible physician(s).
2. Indications for pacing
2.1. Epidemiology, natural history, pathophysiology,
classiﬁcation, and diagnosis of bradyarrhythmias considered
for permanent cardiac pacing therapy2.1.1. Epidemiology
The prevalence of bradyarrhythmias requiring permanent
cardiac pacing therapy is unknown, but an approximation
can be obtained from the analysis of some large databases.
A large variability, between European countries, in number of
pacemaker (PM) implantations has been described that may
reﬂect differences in demographics and disease prevalence,
but could also reﬂect under-provision in some (Fig. 1).
2.1.2. Natural history and role of pacing
Inevitably, knowledge of the natural history of severe bra-
dyarrhythmias comes from very old studies performed at theTable 1 – Classes of recommendations.
Table 2 – Levels of evidence.is therefore inferred, rather than proven by randomized
clinical trials (RCTs).
2.1.3. Atrioventricular block
Death in patients with untreated atrioventricular (AV) block is
due not only to heart failure (HF) secondary to low cardiac
output, but also to sudden cardiac death caused by prolonged
asystole or bradycardia-triggered ventricular tachyarrhythmia.
Pacing is known to prevent recurrence of syncope and
improves survival in adults and in children. In other patients
evidence supports pacing-associated symptomatic and func-
tional improvement.
2.1.4. Sinus node dysfunction
There is no evidence that cardiac pacing prolongs survival in
patients with sick sinus syndrome (SSS). Nevertheless, pacing
improves symptoms and results in lower morbidity (decrease
in systemic embolism and occurrence of atrial ﬁbrillation).
2.1.5. Extrinsic (functional) bradycardia
Since the prognosis is benign—similar to that of the general
population—the only reason for cardiac pacing is to prevent
(traumatic) recurrent syncope.
2.1.6. Pathophysiology and classiﬁcation
Bradyarrhythmias requiring cardiac pacing can be caused by
a variety of aetiologies (Table 3) and the early identiﬁcation
of a potentially reversible cause is the ﬁrst step towards
treatment. The main physiological effect of bradycardia is
lower cardiac output. While the permanent forms of bradyar-
rhythmia are caused by an intrinsic disease of the sinus node
Table 3 – Causes of bradycardia.
Fig. 1 – Average implantation rate of pacemaker (PM) in the 16 western European countries, Poland and Czech Republic (units per
million inhabitants) based on reports from major manufacturers. The ﬁgures include ﬁrst implantations and replacements.
Source: Eucomed (http://www.eucomed.org/medical-technology/facts-ﬁgures).
Table 4 – Typical symptoms of bradycardia (SB and AV
block).
c o r e t v a s a 5 6 ( 2 0 1 4 ) e 5 7 – e 7 4e60or AV conduction system, the aetiology of intermittent
bradyarrhythmia can be difﬁcult to determine.
2.1.7. Diagnosis
Sinus bradycardia (SB) and AV block can be entirely asympto-
matic in young, healthy individuals or during sleep, but
patients with sustained or frequent bradyarrhythmia areoften symptomatic. Easy fatigability, reduced exercise capa-
city and symptoms of HF are common in persistent bradyar-
rhythmia. Dizziness, pre-syncope and syncope are common
symptoms with intermittent severe forms of bradyarrhyth-
mias (Table 4). In general, when a transient or reversible
cause is excluded, the indication for cardiac pacing is deter-
mined by the severity of bradycardia, rather than its aetiol-
ogy. The clinical presentation is more useful for selecting
patients for permanent cardiac pacing therapy (Fig. 2) and
will be followed in these Guidelines [1].
The diagnosis of bradyarrhythmia is usually made from a
standard ECG when persistent, and from a standard ECG or
more prolonged ECG recordings [ambulatory monitoring or
implantable loop recorder (ILR)] when intermittent. The most
useful tests are listed in Table 5.
Fig. 2 – Classiﬁcation of bradyarrhythmias based on the patient's clinical presentation.
Table 5 – Diagnosing bradyarrhythmic syncope after the
initial evaluation: most useful tests.
c o r e t v a s a 5 6 ( 2 0 1 4 ) e 5 7 – e 7 4 e612.2. Persistent bradycardia
This section refers to acquired bradycardia in adults. Refer to
Section 4.3 for bradycardia in children and in congenital heart
disease.
2.2.1. Indications for pacing
2.2.1.1. Sinus node disease (Recommendations 1–3). In gen-
eral, SB is only an indication for pacing if bradycardia is
symptomatic. In patients with sick sinus disease, the demon-
stration of a clear cause–effect relationship between symp-
toms and sinus node disease is often difﬁcult to achieve.
When bradycardia is induced or exacerbated by concomitant
drugs affecting sinus node function, drug discontinuation
should be considered.
2.2.1.2. Acquired atrioventricular block (Recommendations
4–6). In contrast to SB, AV block may require PM therapy
for prognostic reasons and pacing may be indicated in
asymptomatic patients. Available data suggest that pacing
prevents recurrence of syncope and improves survival in
adults. In second-degree type 1 AV block, the indication for
permanent pacing is controversial, unless AV block causes
symptoms or the conduction delay occurs at intra- or infra-
His levels. Tables 6–10.
2.2.2. Choice of pacing mode
Compared with single-chamber-, dual-chamber pacing
results in small but potentially important beneﬁts in patients
with sinus node disease and/or AV block. No difference in
mortality has been observed.2.2.2.1. Sinus node disease (Recommendation 7). In patients with
persistent SB, dual-chamber pacing is the pacing mode of ﬁrst
choice (Fig. 3). Unnecessary right ventricular (RV) pacing should
be systematically avoided in patients with SB, since it may cause
AF and deterioration of HF. In patients with severely reduced left
ventricular ejection fraction (LVEF) and indication for pacing for
sinus node disease, cardiac resynchronization therapy (CRT)
should be considered if a high percentage of ventricular pacing
is to be expected (see Section 3.4 on CRT).2.2.2.2. Acquired atrioventricular block (Recommendation
8). The beneﬁt of dual-chamber over ventricular pacing is
mostly due to the avoidance of PM syndrome, which occurs in
more than a quarter of patients with AV block, and to an
improved exercise capacity (Fig. 3).2.2.2.3. Permanent atrial ﬁbrillation and atrioventricular block
(Recommendation 9). Rate-responsive pacing is associated
with better exercise performance, improved daily activities,
decrease of symptoms of shortness of breath, chest pain and
palpitations and improved quality of life, compared with
ﬁxed-rate pacing (Fig. 3). The minimum rate should be
programmed higher (e.g. 70 bpm) than for SR patients in an
attempt to compensate for loss of active atrial ﬁlling and the
maximum sensor rate should be programmed restrictively
(e.g. 110–120 bpm), in order to avoid ‘overpacing’.2.3. Intermittent (documented) bradycardia
2.3.1. Indications for pacing
2.3.1.1. Sinus node disease, including bradytachy form (Recom-
mendations 1 and 4). Schematically, there are two clinical
features of intermittent bradycardia in patients affected by
intrinsic sinus node disease, in which cardiac pacing is
indicated: A: documented symptomatic intermittent sinus
arrest or sino-atrial block in patients with asymptomatic,
permanent, mild (i.e. heart rate 40–50 bpm) SB, B: prolonged
sinus pause following the termination of tachycardia in the
bradytachy syndrome. When the correlation between symp-
toms and ECG is not established, cardiac pacing may be
Table 7 – Choice of pacing mode/programming in patients with persistent bradycardia.
Table 6 – Indication for pacing in patients with persistent bradycardia.
Table 8 – Indication for pacing in intermittent documented bradycardia.
Table 9 – Indication for cardiac pacing in patients with BBB.
c o r e t v a s a 5 6 ( 2 0 1 4 ) e 5 7 – e 7 4e62
Table 10 – Indication for cardiac pacing in patients with undocumented reﬂex syncope.
Fig. 3 – Optimal pacing mode in sinus node disease and AV block. AF¼atrial ﬁbrillation; AV¼atrioventricular; AVM¼AV delay
management, i.e. to prevent unnecessary right ventricular pacing by means of manual optimization of AV interval or
programming of AV hysteresis; SND¼sinus node disease.
c o r e t v a s a 5 6 ( 2 0 1 4 ) e 5 7 – e 7 4 e63reasonable in patients with intrinsic sinus node disease,
syncope and documentation of asymptomatic pause/s.2.3.1.2. Intermittent/paroxysmal atrioventricular block, includ-
ing atrial ﬁbrillation with slow ventricular conduction (Recom-
mendations 2 and 4). Intermittent/paroxysmal AV block that
occurs in patients with underlying heart disease and/or BBB
is usually regarded as a manifestation of intrinsic disease of
the AV conduction system (Stokes-Adams). There is general
consensus that cardiac pacing is indicated in patients with
intrinsic intermittent AV block, even in the absence of
documentation of symptom–ECG correlation.2.3.1.3. Intermittent bradycardia and asystole in patients with
reﬂex syncope (Recommendations 3 and 4). Differentiation
between the often benign and reversible causes of extrinsic
(reﬂex) sinus arrest and AV block from intrinsic forms is of
practical importance because the beneﬁt of permanent
cardiac pacing is less established. In patients with reﬂexsyncope, cardiac pacing should be the last choice and should
only be given to highly selected patients.2.3.2. Choice of pacing mode
In intermittent bradycardia, pacing may be required only for
short periods of time. In this situation, the beneﬁts of
bradycardia and pause prevention must be weighed against
the detrimental effects of permanent pacing, particularly
pacing-induced HF. The main reason for the preference for
dual-chamber over single-chamber ventricular pacing is the
risk of PM syndrome caused by this latter modality.2.4. Suspected (undocumented) bradycardia
2.4.1. Bundle branch block
The presence of BBB suggests that the cause of syncope may
be complete heart block. Nevertheless, less than half of the
patients with BBB and syncope have a ﬁnal diagnosis of
cardiac syncope. A similar percentage have a ﬁnal diagnosis
Fig. 4 – Therapeutic algorithm for patients presenting with
unexplained syncope and bundle branch block (BBB).
CRT-D¼cardiac resynchronization therapy and deﬁbrillator;
CSM¼carotid sinus massage; EF¼ejection fraction;
EPS¼electrophysiological study; ICD¼implantable
cardioverter deﬁbrillator; ILR¼ implantable loop recorder.
c o r e t v a s a 5 6 ( 2 0 1 4 ) e 5 7 – e 7 4e64of reﬂex syncope and, in about 15%, the cause remains
unexplained at the end of a complete work-up.
Although syncope is not associated with an increased
incidence of sudden death in patients with preserved cardiac
function, a high incidence of total deaths (about one third
sudden) was observed in patients with BBB, especially those
with HF, previous myocardial infarction or low ejection
fraction (EF). An implantable cardioverter deﬁbrillator (ICD)
or a cardiac resynchronization therapy and deﬁbrillator (CRT-
D) should be considered in these patients (see also Section
3.2). Fig. 4.
2.4.1.1. Bundle branch block, unexplained syncope and abnormal
electrophysiological study (Recommendation 1). Electrophysiolo-
gical assessment includes measurement of the His-ventricular
(HV) interval at baseline, with stress by incremental atrial
pacing and with pharmacological provocation (ajmaline, pro-
cainamide or disopyramide).
2.4.1.2. Alternating bundle branch block (Recommendation
2). Alternating BBB (also known as bilateral BBB) refers to
situations in which clear ECG evidence for block in all three
fascicles is manifested on successive ECGs (either right
BBB and left BBB on successive ECGs or right BBB with
associated left anterior fascicular block on one ECG and
associated left posterior fascicular block on another). There
is general consensus that these patients should have pace-
maker implanted even in the absence of syncope.
2.4.1.3. Bundle branch block, unexplained syncope and non-
diagnostic investigations (Recommendation 3). The decision to
implant a PM is determined by an individual risk–beneﬁt
evaluation. There are subsets of patients who might receive a
favourable cost-effective beneﬁt from this strategy; for exam-
ple, old patients with unpredictable (no- or very short
prodromes) and recurrent syncope that expose them to high
risk of traumatic recurrences.
2.4.1.4. Asymptomatic bundle branch block (Recommendation
4). Permanent PM implantation is not indicated for BBB
without symptoms, with the exception of alternating BBB.2.4.2. Reﬂex syncope
Often, reﬂex syncope has an ‘atypical’ presentation. The
diagnosis then relies less on history taking alone and more
on the exclusion of other causes of syncope (absence of
structural heart disease) and on reproducing similar symp-
toms with carotid sinus massage and tilt-table testing.
2.4.2.1. Carotid sinus syncope (Recommendation 1). This syn-
drome is currently deﬁned as syncope with carotid sinus
massage yielding either asystole of 43 s or fall in systolic
blood pressure of 450 mmHg, or both, and reproduction of
the spontaneous syncope. Recommendations for pacing in
carotid sinus syncope are conﬁrmed as before, but a full 10 s
of massage is required; massage is to be performed supine
and erect and pacing (dual chamber) is indicated when 46 s
asystole occurs with reproduction of syncope.
2.4.2.2. Choice of pacing mode (Recommendation 4). The opti-
mal pacing mode is dual-chamber, since VVI mode has been
described as causing an important deterioration.
2.4.2.3. Tilt-induced vasovagal syncope. The rationale for efﬁ-
cacy of cardiac pacing is that the cardio-inhibitory reﬂex is
dominant, since there is no role of pacing in preventing
vasodilatation and hypotension. The lack of reproducibility
of tilt testing limits its utility as a means of assessing therapy.
Cardiac pacing should be limited, as a last resort choice, to a
highly selected small proportion of patients affected by
severe reﬂex syncope.
2.4.2.4. Choice of pacing mode (Recommendation 5). In all
trials, dual-chamber pacing was used, with a rate drop
response feature of the PM that instituted rapid DDD pacing
if the device detected a rapid decrease in heart rate.
2.4.3. Unexplained syncope (and fall)
The cause of syncope may remain unexplained at the end of
a complete work-up performed in accordance with the
recommendations of the 2009 ESC Guidelines for diagnosis
and management of syncope (Recommendation 1–3).3. Indications for cardiac resynchronization
therapy
3.1. Epidemiology, prognosis, and pathophysiology of
heart failure suitable for cardiac resynchronization therapy
Approximately 2% of the adult population in developed countries
has HF; most patients will be aged470 years and about half will
have an LVEF o50%. Based on current guideline criteria, only a
small proportion of patients with HF (perhaps 5–10%) are
indicated for CRT but this is still a large number of patients.
3.1.1. Mortality of heart failure
The prognosis of HF is generally poor. Of patients admitted to
hospital with HF, the 1-year mortality is about 20% in those aged
o75 years and 4 40% if aged 475 years, despite contemporary
pharmacological therapy. An ESC survey found that patients
who received a CRT device had a 1-year mortality of o10%.
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Patients with a broad QRS complex have a worse prognosis
that may only be partially explained by having a lower LVEF.
3.1.3. Role of atrial ﬁbrillation
The overall prevalence of new-onset AF in patients hospita-
lized for congestive heart failure (CHF) was 13%, ranging from
8 to 36%. In chronic HF, the prevalence of AF is linked directly
to disease severity, ranging from 10 to 20% in mild-to-
moderate CHF up to 50% in patients with advanced disease.
3.1.4. Pathophysiology of heart failure relevant to cardiac
resynchronization therapy
Cardiac dyssynchrony is complex and multifaceted. Cardiac
resynchronization therapy helps restore AV, inter- and intra-
ventricular synchrony, improving LV function, reducing func-
tional mitral regurgitation and inducing LV reverse remodel-
ling, as evidenced by increases in LV ﬁlling time and LVEF,Table 11 – Deﬁnition of intraventricular conduction dis-
turbances (adapted from Surawicz et al and Zareba et al).
Table 12 – Indications for cardiac resynchronization therapy inand decreases in LV end-diastolic- and end-systolic volumes,
mitral regurgitation and septal dyskinesis.
3.2. Patients in sinus rhythm
3.2.1. Indications for cardiac resynchronization therapy
3.2.1.1. Patients in New York Heart Association functional class
III–IV. There is conclusive evidence of both short- and long-
term beneﬁts of CRT in patients with New York Heart Associa-
tion (NYHA) class III HF from a series of RCTs. A recent
meta-analysis showed that, in these patients, CRT improved
symptoms and reduced all-cause mortality by 22% (risk ratio
0.78,
95% CI 0.67–0.91) and HF hospitalizations by 35% (risk ratio 0.65,
95% CI 0.50–0.86). The evidence among NYHA class IV heart
failure patients is limited. The magnitude of effect and certainty
of beneﬁt declined with shorter QRS duration than 150ms.
Furthermore, most patients in the RCTs had LBBB morphology
(Table 11).
3.2.1.2. Patients in New York Heart Association functional class
I–II. Four RCTs have demonstrated that CRT improves LV
function, all-cause mortality and HF hospitalizations of
patients with mild HF symptoms (NYHA class I–II), sinus
rhythm, LVEF r30–40% and QRS duration Z120–130 ms. The
recommendation is restricted to patients in NYHA class II and
to patients with complete LBBB. Tables 12–17.
3.2.1.3. Patient selection: role of imaging techniques to evaluate
mechanical dyssynchrony criteria to select patients for cardiac
resynchronization therapy. Imaging techniques may be able to
identify those patients who will respond favourably to CRT.
However, selection of HF patients for CRT based on LV mechan-
ical dyssynchrony assessed with imaging techniques is uncer-
tain and should therefore not be used as a selection criterion
for CRT.
3.2.2. Choice of pacing mode (and cardiac resynchronization
therapy optimization)
The usual (standard) modality of CRT pacing consists of
simultaneous (RV and LV) pacing with a sensed AV delay
programmed between 100 and 120 ms with an LV leadpatients in sinus rhythm.
Table 14 – Summary of current evidence for CRT optimization.
Table 13 – Choice of pacing mode (and cardiac resynchronization therapy optimization).
Table 15 – Indications for cardiac resynchronization therapy in patients with permanent atrial ﬁbrillation.
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Table 16 – Indication for upgraded or de novo cardiac resynchronization therapy in patients with conventional pacemaker
indications and heart failure.
Table 17 – Indication for concomitant implantable cardi-
overter deﬁbrillator (cardiac resynchronization therapy
and deﬁbrillator).
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tion of CRT has the objective of reducing the percentage of
non-responders and is the subject of continuing research.3.2.2.1. Loss of biventricular pacing (Recommendation 1). Sus-
tained and effective biventricular pacing is crucial to achieving
the best results from CRT. Evidence from several clinical studies
indicates that biventricular pacing has to be kept as close as
possible to 100%.3.2.2.2. Selection of left ventricular lead position and single left
ventricular vs. multiple site (Recommendations 2 and 3). The
largest delay in mechanical contraction in an HF patient with
LBBB is most often located in the LV posterolateral region,
which is therefore also the preferred location to place the
LV lead.3.2.2.3. Cardiac resynchronization therapy device optimization.
Despite some promising data from non-randomized trials,
current evidence does not strongly support the performance of
AV and VV optimization routinely in all patients receiving CRT.3.2.2.4. Biventricular pacing vs. left ventricular pacing alone.
Biventricular pacing is the most common mode of delivering
CRT. However, several studies have demonstrated the non-
inferiority of LV pacing alone. LV pacing alone seems particu-
larly appealing in children and young adults (see Section 4.3).3.3. Patients in atrial ﬁbrillation
Only patients with permanent AF or long-standing persistent
AF will be considered in this document.
3.3.1. Patients with heart failure, wide QRS, and reduced
ejection fraction
The LV dysfunction in some AF patients may be a result of a
tachycardiomyopathy process, in others poor LV function is
the result of long-standing HF; both situations are potentially
correctable by rate control strategy using AV junction abla-
tion. ICD back-up should be considered in patients at high
risk of sudden death (see Section 3.5).
3.3.1.1. Heart failure, intrinsic QRS Z120 ms and ejection
fraction r35% (Recommendation 1A and 1B). The prevailing
opinion of experts is in favour of the usefulness of CRT in AF
patients with the same indications as for patients in SR,
provided that AV junction ablation is added in those patients
with incomplete (o99%) biventricular capture. There are no
data regarding NYHA class II patients.
3.3.2. Patients with uncontrolled heart rate who are
candidates for atrioventricular junction ablation
AV junction ablation and permanent pacing from the RV apex
provides highly efﬁcient rate control and regularization of
ventricular response in AF and improves symptoms in
selected patients. CRT may prevent the potential LV dyssyn-
chrony induced by RV pacing and therefore appears an
interesting approach for patients eligible for AV junction
ablation due to rapid AF. Fig. 5.
3.3.2.1. Indications for cardiac resynchronization therapy
(Recommendation 2). There is evidence of an additional ben-
eﬁt of performing CRT pacing in patients with reduced EF,
who are candidates for AV junction ablation for rate control,
in order to reduce hospitalization and improve quality of life.
There is weak evidence that CRT is superior to RV pacing in
patients with preserved systolic function.3.4. Patients with heart failure and conventional
pacemaker indications
For patients with conventional PM who develop HF, upgrad-
ing from VVI or DDD to CRT devices represents an important
part of the patient population implanted with a CRT device,
Fig. 5 – Indication for atrioventricular junction (AVJ) ablation in patients with symptomatic permanent atrial ﬁbrillation (AF)
and optimal pharmacological therapy. BiV¼biventricular; CRT¼cardiac resynchronization therapy; EF¼ejection fraction;
HR¼heart rate; ICD¼implantable cardioverter deﬁbrillator; NYHA¼New York Heart Association.
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A de novo CRT indication in patients with conventional
bradycardia indications is a matter of debate.3.4.1. Patients with an indication for upgrading from
conventional pacemaker or implantable cardioverter
deﬁbrillator to cardiac resynchronization therapy devices.
Previous studies have clearly shown that RV apical pacing
might have deleterious effects on cardiac structure and
function with a positive correlation between the rate of RV
pacing and the occurrence of adverse events.3.4.1.1. Upgrade from conventional pacemaker or implanta-
ble cardioverter deﬁbrillator (Recommendation 1). The
additional beneﬁt of biventricular pacing should be con-
sidered in patients requiring permanent or frequent RV
pacing for bradycardia, who have symptomatic HF and
low LVEF.
Upgrade to CRT is associated with a high complication rate,
which was 18.7% in a recent large prospective trial. The
decision to upgrade should therefore be made after careful
assessment of the risk–beneﬁt ratio (see also Section 5,
Complications).
There is general consensus that, in patients paced for conven-
tional bradycardia indications who, during follow-up, develop
severe symptoms of HF and have depressed EF, an upgrading to
CRT pacing is likely to reduce hospitalization and improve their
symptoms and cardiac performance.3.4.2. De novo cardiac resynchronization therapy pacing in
patients with conventional indication for anti-bradycardia
pacing (Recommendation 2)
There is emerging evidence that de novo CRT implantation
may reduce HF hospitalization, improve quality of life and
reduce symptoms of HF in patients with history of HF,
depressed cardiac function and a bradycardia indication for
pacing. The beneﬁt should be weighed against the addedcomplication rate and costs of CRT devices and their shorter
service life.
3.5. Back-up implantable cardioverter deﬁbrillator in
patients indicated for cardiac resynchronization therapy
3.5.1. Beneﬁt of adding cardiac resynchronization therapy in
patients with indications for implantable cardioverter
deﬁbrillator (Recommendation 1)
Five large randomized trials compared the effects of CRT-D
with ICD alone and showed an advantage for CRT-D in terms
of survival, morbidity and symptom reduction.
3.5.2. Beneﬁt of adding implantable cardioverter deﬁbrillator
in patients with indications for cardiac resynchronization
therapy (Recommendation 2)
Even though the theoretical reason for adding an ICD to CRT
is clear—to reduce the risk of arrhythmic death—the survival
beneﬁt of CRT-D over CRT-P is still a matter of debate.
3.5.2.1. Selection of cardiac resynchronization therapy and
deﬁbrillator or cardiac resynchronization therapy and pacemaker.
There are reasons for preferentially implanting CRT-Ds in
asymptomatic or mildly symptomatic patients—NYHA I–II
patients are younger, have fewer co-morbidities and have a
higher proportion of sudden- vs. non-sudden cardiac deaths. The
possible survival beneﬁt conferred by CRT-D must be balanced
against the risk of ICD-related complications. (Tables 18 and 19).4. Indications for pacing in speciﬁc conditions
4.1. Pacing in acute myocardial infarction
The incidence of new-onset AV block in patients with ST
elevationmyocardial infarction has decreased in the reperfusion
era from 5–7% with thrombolytic therapy to 3.2% with primary
percutaneous coronary intervention. AV block complicating
acute myocardial infarction most often resolves itself sponta-
c o r e t v a s a 5 6 ( 2 0 1 4 ) e 5 7 – e 7 4 e69neously within 2–7 days. In patients with anterior infarction,
complicated by new-onset BBB and transient AV block, short-
and long-term mortality is high irrespective of permanent
pacing. It seems more appropriate to evaluate the indications
for CRT-D, rather than conventional anti-bradycardia pacing
(see Section 3.1).
4.2. Pacing after cardiac surgery, transcatheter aortic
valve implantation, and heart transplantation
The clinically important question in managing post-
operative bradyarrhythmias is related to the reasonable
amount of time to allow for recovery of AV conduction or
sinus node function. If signiﬁcant bradyarrhythmia doesTable 19 – Comparative results of CRT-D vs. CRT-P in
primary prevention.
Table 18 – Clinical guidance to the choice of CRT-P or
CRT-D in primary prevention.
Fig. 6 – Suggested optimal pacing mode in chnot resolve in the suggested observation period after the
procedure, permanent cardiac pacing is indicated with the
same recommendations as in Section 2.2. However, in case
of high-degree or complete AV block with low rate of
escape rhythm, this observation period can be shortened
since resolution is unlikely. For sinus node dysfunction in
heart transplanted patients, the period of observation
could be several weeks.
4.3. Pacing and cardiac resynchronization therapy in
children and in congenital heart disease
Despite many similarities in pacing indications between young
people and adults, several differences justify the writing of a
separate, dedicated chapter. Since children are paced for a
lifetime, they are prone to a higher incidence of long-term
adverse events and are at high risk of experiencing the adverse
consequences of cardiac stimulation at a non-optimal site.
Endocardial leads are contra-indicated in patients with right-to-
left shunt because of the risk of systemic thromboemboli. When
allowed during the surgical intervention, attempts should be
made to stimulate either the left or the systemic ventricle,
although studies looking at chronic results of LV or systemic
pacing are warranted.
4.3.1. Congenital AV block
The decision to proceed with the implantation of a perma-
nent PM in patients suffering from congenital AV block is
strongly inﬂuenced by the awareness that (i) Adams–Stokes
attacks and HF might develop in children, adolescents or
adults of any age and (ii) the ﬁrst manifestation of congenital
AV block might be sudden death, without prodromal symp-
toms and in the absence of manifestations of underlying
heart disease.
4.3.2. Indications for cardiac pacing
(Recommendations 1 and 2)
The development of syncope or pre-syncope, HF or chron-
otropic incompetence limiting the level of physical acti-
vity justiﬁes the implantation of a PM. Prophylactic pac-
ing is indicated in asymptomatic patients who are at
risk of syncope or sudden death, heralded by brady-
cardia, long pauses greater than three times the cycle
length during ventricular escape rhythm, a wide QRSildren (modiﬁed from van Geldorp I et al).
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ectopy.
4.3.3. Post-operative atrioventricular block
In patients with congenital heart disease, post-operative AV
conduction block complicates 1–3% of cardiac operations.
Spontaneous resolution of complete AV block in the early
post-operative period can occur, usually within 10 days after
the operation.
4.3.4. Indications for cardiac pacing
(Recommendations 3 and 4)
There is modest evidence and strong consensus that patients
with persistent third- or second-degree AV block mustTable 21 – Pacing after cardiac surgery, transcatheter aortic va
Table 22 – Indications for pacing therapy in paediatric patient
Table 20 – Indications for permanent pacing.receive permanent cardiac pacing therapy.
4.3.5. Sinus node disease and bradycardia-tachycardia
syndrome
In children, sinus node dysfunction might precede or follow
reparative cardiac surgery involving the atria. Contrary to AV
block, sinus node dysfunction is not associated with
increased mortality.
4.3.6. Indications for cardiac pacing (Recommendations 5 and 6)
The occurrence of symptomatic sinus node disease justiﬁes
the implantation of a PM if competing causes have been
ruled-out after extensive examination. Pacing to restore
chronotropic competence may prevent late post-operative
atrial ﬂutter and reduce exercise intolerance, especially late
after Mustard, Senning or Fontan procedures.
4.3.7. Cardiac resynchronization in congenital heart disease
Evidence of beneﬁt from CRT is limited. A subset of patients
paced in RV for isolated congenital AV block develops a
dilated cardiomyopathy, and in these patients, single-site
LV pacing is particularly attractive (Fig. 6).
4.4. Pacing in hypertrophic cardiomyopathy
4.4.1. Bradyarrhythmia
Atrioventricular block is uncommon in hypertrophic cardio-
myopathy (HCM), but in context, it can suggest speciﬁc aetiol-lve implantation and heart transplantation.
s and congenital heart disease.
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disease and amyloidosis). Atrioventricular block in patients
with HCM should be treated in accordance with the general
recommendations of this Guideline (see Sections 2.1 and 2.2).Table 24 – Pacing in pregnancy.
4.4.2. Treatment of left ventricular outﬂow tract obstruction
(Recommendation 1)
In patients with LV outﬂow tract obstruction treated
with pacemaker or dual-chamber ICD, a short AV interval
programming is crucial. The objective is to achieve maximum
RV apical pre-excitation without compromising LV diastolic
ﬁlling. Finally, a signiﬁcant number of patients with HCM
receive an ICD for primary or secondary prevention.Table 25 – Indication for pacing for ﬁrst-degree atrioven-
tricular block.4.4.3. Cardiac resynchronization therapy
Several case reports and a single centre cohort study have
suggested that CRT pacing alleviated HF symptoms and, in
patients with end-stage HCM, was associated with reverse
remodelling of the left atrium and ventricle.Table 26 – Indication for prevention and termination of
atrial tachyarrhythmias.
Table 27 – Most frequent/important complications of PM
and CRT implantation.4.5. Pacing in rare diseases
Rare diseases (population prevalence less than 1 in 2000)
affect 6–8% of the European population. Some, such as LQTS
or familial AV block, affect only the heart, whereas others are
multi-system disorders with variable cardiac involvement
(Table 19). Bradyarrhythmias in patients with inherited rare
diseases should be treated in accordance with general recom-
mendations of this Guideline (see Sections 2.1 and 2.2).
Numerous rare genetic disorders can cause conduction
disease but, for most, there is little evidence for disease-
speciﬁc treatments, except possibly for laminopathies, in
which early ICD might be considered, and myotonic dystro-
phy, in which PM might be considered if a prolonged HV
interval is detected at EPS. Therefore conventional pacing/ICD
indications should be applied in most cases.Table 23 – Indication for cardiac pacing in patients with
hypertrophic cardiomyopathy.4.6. Pacing in pregnancy
This topic has been recently covered by the ESC Guidelines on
the management of cardiovascular diseases during preg-
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with congenital complete heart block, unless contra-indi-
cated for obstetric reasons. For women who have a stable,
narrow, complex junctional escape rhythm, PM implantation
can be deferred until after delivery. A PM for the alleviation of
symptomatic bradycardia can be implanted at any stage of
pregnancy using echo guidance or electro-anatomic naviga-
tion avoiding ﬂuoroscopy.4.7. Pacing for ﬁrst-degree atrioventricular block
(haemodynamic)
Marked 1st AV block with PR interval 40.3 s may in rare cases
result in symptoms similar to those in PM syndrome. Some
studies have suggested that a reduction of the AV timing using
conventional DDD PM would improve symptoms and patients'
functional status, especially in patients with preserved LV
function.Table 28 – Suggested strategy for management of antiplatelet a
PM/CRT.
Table 29 – Magnetic resonance in patients with implanted car
Table 30 – Remote management of arrhythmias and device.4.8. Algorithms for prevention and termination of atrial
arrhythmias by pacing
The rationale for the use of speciﬁc pacing algorithms is to
avoid bradycardia and large atrial cycle length variations,
which are thought to trigger atrial tachyarrhythmias (AT).
However, there is strong evidence that algorithms
designed to prevent AF have no incremental beneﬁts for the
prevention of AF. Tables 20–26.5. Complications of pacing and CRT
implantation
Pacing and CRT are associated with a substantial rate of
complications (Table 27). In more recent studies, short- and
long-term complications of pacemaker therapy have been
reported to be 12.4% and 9.2%, respectively, after careful
follow-up. Overall complication rates increased sharply as
individual and centre implantation volumes decreased. Leadnd anticoagulant therapy in the peri-implantation period of
diac devices.
Fig. 7 – Safety precautions for magnetic resonance imaging (MRI) in patients with conventional cardiac devices. ATP¼anti-
tachycardiac pacing; ECG¼electrocardiogram; ICD¼implantable cardioverter deﬁbrillator; PM¼pacemaker. Adapted from
Nazarian et al.
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implantation of PM or CRT devices. These have been reported
in 3.6% of patients. The majority of the complications with
pacemakers occur in-hospital or during the ﬁrst 6 months.
Haematomas are very frequent (2.9–9.5% of the cases) and are
usually managed conservatively. Many haematomas can be
avoided by careful haemostasis and preparation of the
patient, allowing correct management of antiplatelet and
anticoagulation therapy (Table 28). Infection is one of the
most worrying post-operative complications. A meta-analysis
of antibiotic prophylaxis using a regimen of pre-procedure
and post-procedure administration suggested a signiﬁcant
reduction in the incidence of infection.6. Management considerations
6.1. Pacing from alternative right ventricular sites
The haemodynamic and clinical effect of pacing from alter-
native RV sites in the His region, mid- or high-ventricular
septum and outﬂow tract has been evaluated in the last two
decades. Analysis of available data suggests that non-apical
RV pacing results in greater LVEF, especially in subjects with
lower LVEFo45 %. No other signiﬁcant advantages have been
proved. Tables 29 and 30.
6.2. Re-implantation of pacemaker/cardiac
resynchronization therapy after device explantation for
infection
Re-implantation is a matter of major concern in patients
treated for PM/CRT infection. Thus, the decision to re-implant
a device should be weighed carefully and indication should
be reassessed. The new PM or CRT should be implanted
at a different site from the explanted, infected system. The
optimal timing for re-implantation is not known. In patients
who are PM-dependent, temporary transvenous pacing is
continued until re-implantation. The ESC Guidelines oninfective endocarditis recommend avoidance of temporary
pacing as much as possible.6.3. Magnetic resonance imaging in patients with
implanted cardiac devices
Since it is estimated that, after implantation, up to 75% of
patients with PMs develop an indication for magnetic reso-
nance imaging (MRI) examination owing to medical co-
morbidities, this Task Force believes it is necessary to provide
recommendations on how to perform an MRI examination
safely in patients with conventional devices.
Suggestions for device programming when magnetic reso-
nance imaging is required are provided in Fig. 7 and in
Recommendations 1 and 2. Patients with leads that have
not matured and those with epicardial and abandoned leads
should be excluded.6.4. Emergency (transvenous) temporary pacing
Complications are common in patients treated with temporary
pacing. Therefore, it should be avoided as far as possible and,
when used, the treatment time should be as brief as possible.
Positive chronotropic drug infusion (e.g. isoproterenol, epinephr-
ine, etc.) may be preferred for a limited time, unless there is a
contra-indication.
Transcutaneous temporary pacing by an external deﬁbril-
lator does not provide reliable ventricular stimulation and
therefore should only be used, under strict haemodynamic
and ECG monitoring, when no other option is available.6.5. Remote management of arrhythmias and device
The usefulness of remote monitoring has been extensively
addressed in the recent joint European and American expert
consensus statement on CRT in heart failure to which
we refer.
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